Viral suppression maintained with alternate-day dosing of efavirenz/tenofovir/emtricitabine
Long-acting injectable treatment maintains viral suppression
Dolutegravir plus darunavir maintains viral suppression without NRTIs
Two-drug protease inhibitor treatment as effective as three-drug treatment – and fewer stop due to side-effects
Studies confirm long-term effectiveness of new single-tablet regimens
Dual-antibody combination therapy produces three to seven months of viral suppression without pills
Dolutegravir dual therapy works well for first-time HIV treatment
